A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 120
- Registration Number
- NCT06630234
- Locations
- 🇺🇸
HonorHealth, Scottsdale, Arizona, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 36
- Registration Number
- NCT06619561
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸Avera Cancer Institute, Sioux Falls, South Dakota, United States
Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway
- First Posted Date
- 2024-03-01
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 140
- Registration Number
- NCT06287463
- Locations
- 🇺🇸
University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸SCRI HealthONE, Denver, Colorado, United States
A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies
- First Posted Date
- 2023-07-24
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 94
- Registration Number
- NCT05957367
- Locations
- 🇺🇸
University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UCLA Department of Medicine-Hematology/Oncology, Los Angeles, California, United States
🇺🇸Sylvester Comprehensive Cancer Center, Miami, Florida, United States
A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 54
- Registration Number
- NCT05734105
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇨🇦Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)
- Conditions
- Interventions
- First Posted Date
- 2021-10-18
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Registration Number
- NCT05080621
Study of Vimseltinib for Tenosynovial Giant Cell Tumor
- Conditions
- Interventions
- First Posted Date
- 2021-09-28
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 120
- Registration Number
- NCT05059262
- Locations
- 🇪🇸
Hospital Universitario Vall d'Hebron, Barcelona, Spain
🇺🇸Ohio State University, Columbus, Ohio, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
A Phase 1/2 Study of DCC-3116 in Patients With RAS/MAPK Pathway Mutant Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 173
- Registration Number
- NCT04892017
- Locations
- 🇺🇸
Siteman Cancer Center, Saint Louis, Missouri, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Rutgers Cancer Institute, New Brunswick, New Jersey, United States
A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients With Advanced GIST
- Conditions
- Interventions
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 13
- Registration Number
- NCT04530981
- Locations
- 🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST
- Conditions
- First Posted Date
- 2019-11-01
- Last Posted Date
- 2020-05-29
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Registration Number
- NCT04148092